FIGURE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors | Synapse
April 30, 2024
FIGURE 1 from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Key Points
Key points are not available for this paper at this time.
Abstract
KIN3248 mean concentrations (mean ± SD) in patients following oral daily administration of KIN-3248 during cycle 1 day 1 and day 2.